Piper Sandler maintains Corcept Therapeutics at Overweight, raises price target to $173 from $165

Piper Sandler kept its Overweight rating on Corcept Therapeutics and increased its price target to $173 from $165, suggesting a 111.2% upside from the Nov 3 close of $81.93, according to the firm.

Original reporting
Published Nov 4, 2026, 5:20 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 4, 2026, 5:24 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Piper Sandler maintains Corcept Therapeutics at Overweight, raises price target to $173 from $165 — source image
Decision brief

The 30-second read

Med
01

Why it matters

The price‑target raise may trigger short‑covering and new buying, but actual stock movement depends on upcoming clinical data.

02

Market read

Analyst upgrade provides a fresh catalyst for a small‑cap biotech, offering a modest trading opportunity.

03

What to watch

Potential regulatory or trial setbacks not reflected in the target.

Relevance 6/10Novelty 6/10Timing: today

Background

Corcept Therapeutics is a biotech focused on cortisol‑related therapies; analyst coverage is sparse.

Market effects

May lift sentiment in the biotech sector as analysts show confidence in Corcept's pipeline.

Limited to U.S. biotech investors.

Minimal global impact.

Counterpoint

The target increase could be premature if upcoming trial data disappoints.

Key entities

  • Piper Sandler

    Issued the upgraded price target.

  • Corcept Therapeutics

    Biotech firm receiving the upgraded target.

Related articles

$CORTMedAI 8/10

Corcept reports 8-year response in vulvar cancer case study

Corcept Therapeutics (CORT) reported a case study in ESMO Rare Cancers showing an 8-year response to relacorilant plus nab-paclitaxel in a metastatic vulvar cancer patient. The company noted this is a single case and not representative of the broader population. Relacorilant is FDA-approved for platinum-resistant ovarian cancer but not vulvar cancer. Corcept is developing the drug for other cancer types.

$CORTMed

Corcept Therapeutics Inc (CORT) (Q3 2026) Earnings Call Highlights: Revenue Surges 64%

Corcept Therapeutics (CORT) reported Q3 2026 revenue of $91M, up 64% YoY, driven by Lifyorli's growth. Management expects Lifyorli to move earlier in treatment sequences and sees potential for $1B in revenue. The company reiterated its 2026 guidance of $1.1B-$1.2B, citing strong performance in endocrinology and oncology. CEO Belanoff discussed upcoming clinical trials and potential combinations for Lifyorli.

$CORTMedAI 8/10

Corcept Therapeutics Q3 Earnings Call Highlights

Corcept Therapeutics (CORT) reported positive results from its BELLA Phase 2 trial, with relacorilant showing median progression-free survival of 7.2 months and a 59% response rate. The FDA is set to decide on relacorilant's application for Cushing's syndrome by December 17. Corcept also outlined ongoing trials for relacorilant in various cancers and miricorilant in MASH, with results expected by 2027. The company plans to initiate a Phase 3 ALS study next year.